Methods of treatment with an ocular implant containing a tyrosine kinase inhibitor
AssigneeOcular Therapeutix, Inc.
InventorsCharles D. Blizzard, Arthur Driscoll, Rami El-Hayek, Michael Goldstein, Joseph Iacona, Peter Jarrett, Timothy S. Jarrett, Erica Kahn, Zachary Lattrell
Life of this patent
Estimating the term…
Abstract
This invention relates to methods of treatment with a sustained release biodegradable ocular implant containing a tyrosine inhibitor dispersed in a hydrogel.
Claims29
A method of treating an ocular disease in a patient in need thereof, the method comprising administering to the patient a sustained release biodegradable ocular implant comprising a hydrogel and a dose of axitinib from about 150 μg to about 1200 μg, wherein the axitinib is dispersed within the hydrogel, and wherein the implant in its dry state prior to implantation is cylindrical;
- has a length of about 6 mm to about 17 mm and a diameter of 0.2 mm to 0.5 mm;
- and has a total implant weight of about 0.2 mg to about 1.5 mg.
Dependencies are inferred from the claim text.